Indication |
Used as an aid for the diagnosis of pheochromocytoma, and may be
administered immediately prior to or during pheochromocytomectomy to
prevent or control paroxysmal hypertension resulting from anesthesia,
stress, or operative manipulation of the tumor. Phentolamine has also
been used to treat hypertensive crisis caused by sympathomimetic amines
or catecholamine excess by certain foods or drugs in patients taking MAO
inhibitors, or by clonidine withdrawal syndrome. Other indications
include the prevention of dermal necrosis and sloughing following IV
administration or extravasation of norepinephrine, decrease in impedance
to left ventricular ejection and the infarct size in patients with MI
associated with left ventricular failure, treatment of erectile
dysfunction through self-injection of small doses combined with
papaverine hydrochloride into the corpus cavernosum, and as an adjunct
to the management of cocaine overdose to reverse coronary
vasoconstriction following use of oxygen, benzodiazepines,and
nitroglycerin. |
Pharmacodynamics |
Phentolamine is indicated for the control of episodes of
hypertension and sweating that occur with a disease called
pheochromocytoma. If tachycardia is excessive, it may be necessary to
use a beta-blocking agent concomitantly. Phentolamine is a long-acting,
adrenergic, alpha-receptor blocking agent which can produce and maintain
"chemical sympathectomy" by oral administration. It increases blood
flow to the skin, mucosa and abdominal viscera, and lowers both supine
and erect blood pressures. It has no effect on the parasympathetic
system. Phentolamine works by blocking alpha receptors in certain parts
of the body. Alpha receptors are present in the muscle that lines the
walls of blood vessels. When the receptors are blocked by Phentolamine,
the muscle relaxes and the blood vessels widen. This widening of the
blood vessels results in a lowering of blood pressure. |
Mechanism of action |
Phentolamine produces its therapeutic actions by competitively
blocking alpha-adrenergic receptors (primarily excitatory responses of
smooth muscle and exocrine glands), leading to a muscle relaxation and a
widening of the blood vessels. This widening of the blood vessels
results in a lowering of blood pressure. The action of phentolamine on
the alpha adrenergic receptors is relatively transient and the blocking
effect is incomplete. The drug is more effective in antagonizing
responses to circulating epinephrine and/or norepinephrine than in
antagonizing responses to mediator released at the adrenergic nerve
ending. Phentolamine also stimulates β-adrenergic receptors and produces
a positive inotropic and chronotropic effect on the heart and increases
cardiac output. |
Absorption |
Not Available |
Volume of distribution |
Not Available |
Protein binding |
Not Available |
Metabolism |
Not Available |
Route of elimination |
10-13% of the drug is excreted unchanged in urine, and the fate of the remainder of the drug is unknown. |
Half life |
19 minutes |
Clearance |
Not Available |
Toxicity |
Not Available |